Adjuvant analgesics in cancer pain: A review

Raj Mitra, Stephanie Jones

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Adjuvant analgesics (co-analgesics) are medications whose primary indication is the management of a medical condition with secondary effects of analgesia. Cancer pain is multifactorial and often involves inflammatory, nociceptive, and neuropathic pain subtypes. Adjuvant analgesics used in conjunction with opioids have been found to be beneficial in the management of many cancer pain syndromes; however, they are currently underutilized. Antidepressants, anticonvulsants, local anesthetics, topical agents, steroids, bisphosphonates, and calcitonin are all adjuvants which have been shown to be effective in the management of cancer pain syndromes. When utilizing analgesic adjuvants in the treatment of cancer pain, providers must take into account the particular side effect profile of the medication. Ideally, adjuvant analgesics will be initiated at lower dosages and escalated as tolerated until efficacy or adverse effects are encountered.

Original languageEnglish (US)
Pages (from-to)70-79
Number of pages10
JournalAmerican Journal of Hospice and Palliative Medicine
Volume29
Issue number1
DOIs
StatePublished - Feb 2012

Fingerprint

Analgesics
Nociceptive Pain
Diphosphonates
Calcitonin
Neuralgia
Local Anesthetics
Anticonvulsants
Analgesia
Opioid Analgesics
Antidepressive Agents
Anesthetics
Steroids
Cancer Pain
Therapeutics

Keywords

  • adjuvant
  • analgesic
  • cancer and pain

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Adjuvant analgesics in cancer pain : A review. / Mitra, Raj; Jones, Stephanie.

In: American Journal of Hospice and Palliative Medicine, Vol. 29, No. 1, 02.2012, p. 70-79.

Research output: Contribution to journalArticle

@article{fa1f71c9fdd8410d8445806f6be9ba01,
title = "Adjuvant analgesics in cancer pain: A review",
abstract = "Adjuvant analgesics (co-analgesics) are medications whose primary indication is the management of a medical condition with secondary effects of analgesia. Cancer pain is multifactorial and often involves inflammatory, nociceptive, and neuropathic pain subtypes. Adjuvant analgesics used in conjunction with opioids have been found to be beneficial in the management of many cancer pain syndromes; however, they are currently underutilized. Antidepressants, anticonvulsants, local anesthetics, topical agents, steroids, bisphosphonates, and calcitonin are all adjuvants which have been shown to be effective in the management of cancer pain syndromes. When utilizing analgesic adjuvants in the treatment of cancer pain, providers must take into account the particular side effect profile of the medication. Ideally, adjuvant analgesics will be initiated at lower dosages and escalated as tolerated until efficacy or adverse effects are encountered.",
keywords = "adjuvant, analgesic, cancer and pain",
author = "Raj Mitra and Stephanie Jones",
year = "2012",
month = "2",
doi = "10.1177/1049909111413256",
language = "English (US)",
volume = "29",
pages = "70--79",
journal = "American Journal of Hospice and Palliative Medicine",
issn = "1049-9091",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Adjuvant analgesics in cancer pain

T2 - A review

AU - Mitra, Raj

AU - Jones, Stephanie

PY - 2012/2

Y1 - 2012/2

N2 - Adjuvant analgesics (co-analgesics) are medications whose primary indication is the management of a medical condition with secondary effects of analgesia. Cancer pain is multifactorial and often involves inflammatory, nociceptive, and neuropathic pain subtypes. Adjuvant analgesics used in conjunction with opioids have been found to be beneficial in the management of many cancer pain syndromes; however, they are currently underutilized. Antidepressants, anticonvulsants, local anesthetics, topical agents, steroids, bisphosphonates, and calcitonin are all adjuvants which have been shown to be effective in the management of cancer pain syndromes. When utilizing analgesic adjuvants in the treatment of cancer pain, providers must take into account the particular side effect profile of the medication. Ideally, adjuvant analgesics will be initiated at lower dosages and escalated as tolerated until efficacy or adverse effects are encountered.

AB - Adjuvant analgesics (co-analgesics) are medications whose primary indication is the management of a medical condition with secondary effects of analgesia. Cancer pain is multifactorial and often involves inflammatory, nociceptive, and neuropathic pain subtypes. Adjuvant analgesics used in conjunction with opioids have been found to be beneficial in the management of many cancer pain syndromes; however, they are currently underutilized. Antidepressants, anticonvulsants, local anesthetics, topical agents, steroids, bisphosphonates, and calcitonin are all adjuvants which have been shown to be effective in the management of cancer pain syndromes. When utilizing analgesic adjuvants in the treatment of cancer pain, providers must take into account the particular side effect profile of the medication. Ideally, adjuvant analgesics will be initiated at lower dosages and escalated as tolerated until efficacy or adverse effects are encountered.

KW - adjuvant

KW - analgesic

KW - cancer and pain

UR - http://www.scopus.com/inward/record.url?scp=84856588738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856588738&partnerID=8YFLogxK

U2 - 10.1177/1049909111413256

DO - 10.1177/1049909111413256

M3 - Article

C2 - 21712306

AN - SCOPUS:84856588738

VL - 29

SP - 70

EP - 79

JO - American Journal of Hospice and Palliative Medicine

JF - American Journal of Hospice and Palliative Medicine

SN - 1049-9091

IS - 1

ER -